Optimi Health (OPTI) AI Stock Analysis

• Market Cap: C$28.03M
• Dividend Yield: N/A
• Average Volume (3M): 169.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: 65.16%
• EPS Growth: 33.18%
• Country: CA
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Agricultural Farm Products
• EPS (TTM): >-0.01
• Shares Outstanding: 96,638,170
• 10 Day Avg. Volume: 137,724
• 30 Day Avg. Volume: 169,715
• PEG Ratio: -0.28
• Price to Book (P/B): 2.24
• Price to Sales (P/S): 55.12
• P/FCF Ratio: -4.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: C$0.50 ▲(56.25% Upside)

Optimi Health's overall score is primarily impacted by its financial performance, which shows potential but is hindered by persistent losses and cash flow challenges. Technical analysis provides some positive momentum signals, but valuation concerns due to negative earnings weigh heavily on the score.

Positive Factors

Revenue Growth

The consistent revenue growth indicates an expanding customer base and successful market penetration, which can drive future profitability.

Strong Equity Levels

A strong equity position suggests financial stability and provides a buffer against potential financial downturns, supporting long-term growth.

Gross Profit Margin

A high gross profit margin reflects effective cost management and pricing power, which can enhance profitability as the company scales.

Negative Factors

Persistent Losses

Ongoing losses highlight operational inefficiencies and may hinder the company's ability to achieve profitability without significant changes.

Negative Cash Flows

Inadequate cash flow to cover net losses indicates cash management issues, which could limit investment in growth and innovation.

Reliance on External Funding

Dependence on external funding can increase financial risk and limit strategic flexibility, potentially impacting long-term sustainability.

Optimi Health Business Overview & Revenue Model

Company Description

Optimi Health Corp. develops an integrated functional mushroom brand that focuses on the health and wellness food markets in Canada. The company also focuses on the cultivation, extraction, processing, and distribution of strains of functional mushroom. It offers a range of fungi varieties, which include Lions Mane, Reishi, Turkey Tail, Chaga, and Cordyceps. The company was formerly known as 1251418 BC Ltd. and changed its name to Optimi Health Corp. in August 2020. Optimi Health Corp. was incorporated in 2020 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Optimi Health generates revenue through multiple channels including subscription fees for its telehealth and online therapy services, which provide users with access to licensed mental health professionals. Additionally, the company may earn income from partnerships with employers and organizations that integrate its wellness programs into their employee health initiatives. The revenue model is further supported by potential licensing agreements for its proprietary digital health technologies and platforms. Strategic collaborations with healthcare providers and insurers can also contribute to revenue growth by expanding the reach of its services and enhancing its offerings.

Optimi Health Financial Statement Overview

Summary

Optimi Health shows revenue growth and strong equity levels, indicating potential for future profitability. However, persistent losses, negative cash flows, and reliance on external funding pose significant financial risks. The company needs to improve operational efficiency and cash management.

Income Statement

Optimi Health's revenue has shown growth from $0 in 2020 to $389,850 in 2024, indicating an upward trend. However, the company has consistently reported negative net income, with a significant net loss of $6,035,859 in 2024. The gross profit margin for 2024 is relatively healthy at 69.5%, but the absence of EBIT and negative EBITDA highlight challenges in operational efficiency.

Balance Sheet

The company maintains a high equity ratio, with stockholders’ equity consistently exceeding total liabilities, indicating financial stability. The debt-to-equity ratio is moderate at 0.29 in 2024, suggesting manageable leverage. However, the declining trend in total assets and stockholders' equity since 2021 should be monitored.

Cash Flow

Optimi Health's cash flow demonstrates a challenging picture with negative operating and free cash flows in all observed years, reflecting cash management issues. The operating cash flow to net income ratio is negative, underscoring cash flow inadequacy to cover net losses. Despite positive financing cash flows, reliance on external financing is evident.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	548.19K	389.85K	181.09K	80.72K	0.00	0.00
Gross Profit	-195.26K	270.91K	-157.04K	53.92K	-47.12K	-5.42K
EBITDA	-2.68M	-4.74M	-4.42M	-7.03M	-5.95M	-161.14K
Net Income	-4.09M	-6.04M	-5.19M	-7.38M	-6.04M	-169.22K
Balance Sheet
Total Assets	14.14M	14.55M	16.49M	16.82M	23.46M	6.17M
Cash, Cash Equivalents and Short-Term Investments	88.53K	103.66K	1.34M	1.89M	12.43M	4.47M
Total Debt	2.86M	2.75M	1.71M	157.58K	250.84K	156.32K
Total Liabilities	6.38M	4.98M	3.28M	797.66K	2.40M	882.66K
Stockholders Equity	7.75M	9.58M	13.21M	16.02M	21.07M	5.29M
Cash Flow
Free Cash Flow	-2.06M	-4.43M	-4.41M	-11.73M	-10.96M	-898.27K
Operating Cash Flow	-1.94M	-4.28M	-3.60M	-4.58M	-6.02M	-143.45K
Investing Cash Flow	-91.52K	-154.02K	-706.02K	-3.15M	-9.19M	-754.83K
Financing Cash Flow	1.87M	3.19M	3.76M	1.19M	19.18M	5.37M

Optimi Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.32
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Positive. The current price of 0.32 is above the 20-day moving average (MA) of 0.32, below the 50-day MA of 0.34, and above the 200-day MA of 0.25, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 49.65 is Neutral, neither overbought nor oversold. The STOCH value of 36.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:OPTI.

Optimi Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NLH	62 Neutral	C$24.45M	22.92	4.10%	―	19.61%	―
ROMJ	55 Neutral	C$32.92M	10.74	7.78%	―	28.55%	―
CWEB	52 Neutral	C$81.30M	-2.61	-109.83%	―	-4.23%	37.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OPTI	51 Neutral	C$28.03M	-7.34	-44.37%	―	65.16%	33.18%
PHRM	45 Neutral	C$8.65M	-5.34	-112.32%	―	―	27.35%

Optimi Health Corporate Events

Optimi Health Adds Risk Management Veteran Jason Mosberian to Board

Optimi Health has appointed Jason Mosberian to its board of directors, replacing outgoing director Jonathan Schintler, with the move subject to Canadian Securities Exchange approval. Mosberian, a CPA and Senior Vice President and Partner at BFL Canada, brings more than a decade of experience in risk management and insurance across manufacturing, distribution and life sciences, bolstering governance and risk oversight at the psychedelic drug manufacturer as it expands its regulated pharmaceutical operations.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Optimi Health to Supply MDMA for Israeli PTSD Clinical Trial

Optimi Health has been chosen to supply MDMA capsules for a clinical trial in Israel, sponsored by Sheba Medical Center, aimed at treating trauma-related PTSD. The trial, part of MAPS Israel’s Healing October 7th initiative, will assess the effectiveness of group versus individual MDMA-assisted therapy for 168 patients. This collaboration marks a significant step for Optimi’s MDMA product, potentially expanding access to PTSD treatment and enhancing the company’s position in the psychedelic-assisted therapy industry.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Optimi Health Achieves GMP Compliance and Enhances Market Liquidity

Optimi Health Corp. has successfully passed its Drug Establishment Licence inspection by Health Canada, achieving a GMP-compliant rating for the fabrication and distribution of pharmaceutical-grade psychedelic products. This certification allows Optimi to manufacture, label, package, distribute, and wholesale pharmaceutical psychedelics, including MDMA and psilocybin capsules for treating PTSD and TRD, which are currently prescribed in Australia. Additionally, Optimi has entered into a market-making service agreement with Independent Trading Group to enhance the liquidity of its shares on the Canadian Securities Exchange, aiming to maintain an orderly market.